Based on the Supriya Lifescience Limited stock forecast from 1 analysts, the average analyst target price for Supriya Lifescience Limited is INR 272.00 over the next 12 months. Supriya Lifescience Limited’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Supriya Lifescience Limited is Slightly Bullish , which is based on 7 positive signals and 4 negative signals. At the last closing, Supriya Lifescience Limited’s stock price was INR 402.30. Supriya Lifescience Limited’s stock price has changed by +9.45% over the past week, +18.05% over the past month and +78.72% over the last year.
No recent analyst target price found for Supriya Lifescience Limited
No recent average analyst rating found for Supriya Lifescience Limited
Company Overview Supriya Lifescience Limited
Supriya Lifescience Limited engages in the research and development, manufacture, and sale of bulk drugs and pharmaceutical chemicals worldwide. It offers anti-allergic, anti-asthmatic, decongestant, analgesic/anti-pyretic/anesthetic, anti"hypertensive, and anti-malarial products, as well as vitamins and xanthine derivatives. The company was founded in 1987 and is headquartered in Mumbai, India. Read Less
Supriya Lifescience Limited engages in the research and development, manufacture, and sale of bulk drugs and pharmaceutical chemicals worldwide. It offers anti-allergic, anti-asthmatic, decongestant, analgesic/anti-pyretic/anesthetic, anti"hypertensive, and anti-malarial products...Read More
Frequently Asked Questions About Supriya Lifescience Limited (SUPRIYA:NSE) Stock
Based on ratings from 1 analysts Supriya Lifescience Limited's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Slightly Bullish . The stock has 1 buy, sell and hold ratings.
SUPRIYA:NSE stock's dividend yield is 0.16%.
Our analysis grades SUPRIYA:NSE stock's dividend yield at F. This means that SUPRIYA:NSE stock's dividend yield is above 40% of the stocks in the Biotechnology sector in the NSE exchange.
Based on this SUPRIYA:NSE may be a average dividend stock for its sector.
Based on targets from 1 analysts, the average taret price for SUPRIYA:NSE is INR 272.00 over the next 12 months. The maximum analyst target price is INR 272 while the minimum anlayst target price is INR 272.
SUPRIYA:NSE stock's Price/Earning ratio is 25.58.
Our analysis grades SUPRIYA:NSE stock's Price / Earning ratio at B-. This means that SUPRIYA:NSE stock's Price/Earning ratio is above 20% of the stocks in the Biotechnology sector in the NSE exchange.
Based on this SUPRIYA:NSE may be undervalued for its sector.
The last closing price of SUPRIYA:NSE's stock was INR 402.30.
The most recent market capitalization for SUPRIYA:NSE is INR 30.78B.
Based on targets from 1 analysts, the average taret price for SUPRIYA:NSE is projected at INR 272.00 over the next 12 months.
This means that SUPRIYA:NSE's stock price may go down by -32.39% over the next 12 months.
We can't find any ETFs which contains Supriya Lifescience Limited's stock.
As per our most recent records Supriya Lifescience Limited has 392 Employees.
Supriya Lifescience Limited's registered address is 207/208 Udyog Bhavan, Mumbai, India, 400063.
You can get more information about it from Supriya Lifescience Limited's website at https://www.supriyalifescience.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Low volatility
The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.
Positive cash flow
The company had positive total cash flow in the most recent four quarters.
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
Superior return on assets
The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.
Superior capital utilization
The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.
Underpriced compared to earnings
The stock is trading low compared to its peers on a price to earning basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.
Superior return on equity
The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
Below median dividend returns
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
Poor risk adjusted returns
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
Overpriced on cashflow basis
The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for SUPRIYA:NSE !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
Stocktwits
